Visão geral da empresa
A clinical-stage biopharmaceutical company, Cue Biopharma, Inc., is dedicated to developing a novel class of injectable therapeutics designed to selectively engage and modulate targeted, disease-relevant T cells within the United States market. The enterprise operates within the Healthcare sector, specifically functioning in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at creating new biological medicines. According to the available data, the company's scale is defined by a market capitalization of $28.60M, annual revenue of $27.47M, and a workforce consisting of 29 employees. These figures indicate that the company maintains a relatively small market presence typical of early-stage biotech firms, where revenue generation is often still in the early phases of commercialization or expansion while the workforce remains lean to conserve capital for development pipelines. The disparity between the revenue of $27.47M and the market cap of $28.60M suggests a valuation that closely mirrors current sales figures, a characteristic often seen in companies that have not yet established significant profit margins or a large installed base of products.
Saúde financeira
The company reported revenue of $27.47M for the trailing twelve months, accompanied by a net income of -$26.602M and an EBITDA of -$25.563M. The substantial gap between the positive revenue of $27.47M and the significant negative net income reveals a cost structure where operating expenses, likely dominated by research and development costs, far exceed the gross income generated from sales. Free cash flow stands at -$9.95175M, indicating that the company is currently burning cash through its operations and development activities, which limits immediate financial flexibility and necessitates reliance on existing cash reserves or external financing. The gross margin is reported as -26.9%, a negative figure that suggests costs of goods sold are currently exceeding gross revenue, a common scenario in the early stages of launching new biologic products. The operating margin is 8.9%, which contrasts sharply with the negative profit margin of -96.9%, highlighting the specific impact of non-operating expenses or significant one-time costs on the bottom line that depress the overall profitability. Regarding balance sheet strength, total cash holdings of $28.23M provide liquidity against total debt of $4.20M, resulting in a debt-to-equity ratio of 15.88, which indicates a capital structure heavily weighted toward equity financing rather than debt leverage. The current ratio is 2.74, a metric that signifies the company holds sufficient current assets to cover its short-term liabilities nearly three times over, suggesting robust short-term liquidity despite the negative earnings. Furthermore, the return on equity is -121.1% and the return on assets is -44.6%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate negative returns, a typical characteristic of clinical-stage entities investing heavily in pipeline development before achieving commercial profitability.
Avaliação de valorização
The trailing P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is -0.61, a valuation metric that reflects the company's projected losses and indicates that traditional earnings-based valuation methods are not applicable in the current context. The price-to-book ratio is 1.07, suggesting that the market values the company's equity at a slight premium over its book value, which can occur when investors anticipate future asset appreciation or intangible value not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 1.04 and an EV/EBITDA of -0.18, which suggest that the company is trading at a valuation roughly equal to its revenue, a common benchmark for pre-profitability biotechnology firms where sales growth is the primary driver of value. The stock's recent price action ranges between a 52-week high of $1.03 and a 52-week low of $0.17, and without a specific current price provided in the facts, the positioning relative to this range cannot be calculated; however, the wide spread indicates significant volatility. The beta value is 1.58, which implies that the stock price exhibits higher volatility relative to the broader market, moving approximately 1.58 times as much as the market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is reported at an extraordinary 1292.3%, while earnings growth is N/A due to the company's continued losses, indicating that the rapid expansion in revenue is not yet translating into profitability. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all earnings are reinvested into growth initiatives rather than distributed to shareholders. The absence of a dividend payout ratio is consistent with the company's stage of development, where capital retention is prioritized to fund research and development and operational scaling. The overall growth and income profile is characterized by explosive revenue expansion coupled with negative earnings and no current income distribution, reflecting a classic high-growth, pre-revenue biotechnology business model where value is derived from pipeline potential rather than current cash flow.